#### Animal Health Innovation Asia 2019 Tokyo, November 6<sup>th</sup>, 2019

Regulatory Pathways and Market Access in Japan

YUKI UJIMASA, DVM, MS AHRMS, INC.

# Self Introduction / YUKI UJIMASA, DVM, MS

- Family : Wife, 1 Cat, and 3 Dogs
- Working Experiences
- 1988-2005 Dainippon Pharmaceutical Co., Ltd.
- °2006-Present F
- °2010-Present
- °2013-Present

- President, AHRMS, Inc.
- Director of Boards, EBM Trading Japan, K.K.

President, Vm3, Inc.

Japanese No.1 Distributor of Horse Medicines since 2017

Web-based veterinary media and consultation. In 2020, wholesale and retail will start.

# AHRMS, Inc.

### **Business Menu:**

#### 1. Public Affairs

- VICH Pharmacovigilance / VICH Electric Document Transfer
- Japanese Society of Clinical Veterinary Medicine
- 2. Registration of animal medicines and devices
- 3. Designated Marketing Authorization Holder (D-MAH)



- 4. Marketing Support for industries to vets and pet owners
- 5. Market Analysis, Prediction, Writing and Lectures

# Agenda



- 1. How to register new animal medicines by JMAFF
- 2. Further acceleration of evaluation by JMAFF
- 3. 4 ways to register and distribute new animal medicines
- 4. How to effectively promote and distribute your products to animal hospitals and pet owners in Japan
- 5. Whether Vets' online shops can be adopted in Japan?
- 6. How to tackle falsified products

1. How to register new animal medicines by JMAFF

- Five categories of new animal medicines
  - (1) A drug containing a new active ingredient in Japan
  - (2) A drug with a new dosage regimen
  - (3) A drug with a new dose and drugs with new indications
  - (4) A drug with a new combination of active ingredients
  - (5) A generic drug that is identical to the existing VMPs

\*VMPs: Veterinary Medicinal Products

1.How to register new animal medicines by JMAFF
Data set required for application for VMPs in Japan

#### Data Item

- A Origin or development history, usage situation in foreign countries
- B Physico-chemical test data (e.g. physico-chemical property, specifications and assay procedures)
- C Manufacturing processes
- D Stability Test (e.g. long-term storage test, stress test, accelerated test)
- E Toxicity Test (Acute toxicity, Subacute toxicity, Chronic, and Special toxicity)
- F Target Animal Safety Test
- G Pharmacology test (Test as evidence of efficacy, and General pharmacology test)
- H ADME
- I Clinical Test
- J Residue Test

(Source: JMAFF NVAL)


R: Required to be attached, N: Not required, D: Depends on each drug

# 1.How to register new animal medicines by JMAFF Data set required for application for VMPs in Japan

	Data Item	(1) New Ingredient	(2) New Dosage	(3) New Indication	(4) New Combination	(5) Generic
А	Origin or development history, usage situ	R	R	R	R	N
В	Physico-chemical test data (e.g. physico	R	D	D	R	D
С	Manufacturing processes	R	D	D	D	D
D	Stability Test (e.g. long-term storage test	R	D	D	R	D
Е	Toxicity Test (Acute toxicity, Subacute tox	D	D	Ν	D	Ν
F	Target Animal Safety Test	R	R	D	R	D
G	Pharmacology test (Test as evidence of	R	D	D	R	Ν
Н	ADME	R	D	D	R	D
1	Clinical Test	R	R	R	R	Ν
J	Residue Test	R	R	D	R	D
	(Source: IMAEE NIVAL) R: Required to be attached N: Not required D: Depends on each drug					

(Source: JMAFF NVAL)

R: Required to be attached, N: Not required, D: Depends on each drug



# 2. Further Acceleration of Evaluation by JMAFF

Results of evaluation periods of drugs approved in 2017

- Standard processing period: 12 months
- <u>All approved drugs (208 items)</u>
  - Periods on JMAFF side: 80 percentile value: 11.7 months
     Whole periods: 80 percentile value: 16.6 months
- Drugs needed to receive consultation by PAFSC (30 items)
   ➢ Periods on JMAFF side: mean value: 16.2 months
   ➢ Whole periods: mean value: 24.6 months
- Drugs NOT needed to receive consultation by PAFSC (178 items)
   ➢ Periods on JMAFF side: 80 percentile value : 10.5 months
   ➢ Whole periods: 80 percentile value : 13.9 months

(Source: JMAFF)

# 2. Further Acceleration of Evaluation by JMAFF

#### Numerical Target

(Source: JMAFF)

- <u>All approved drugs:</u>
  - ➢Periods on JMAFF side: 80 percentile value: Less than 12 months
- <u>Drugs needed to receive consultation by PAFSC</u>
  - ➢ Periods on JMAFF side: mean value: Less than 12 months by 2023
- Drugs NOT needed to receive consultation by PAFSC

➢Periods on JMAFF side: 80 percentile value: Less than 12 months

"In order to receive the approvals as early as possible, we, applicants, have to try to shorten our in-house documentation periods!" 3. Four ways to register and distribute new animal medicines

Rationale: The Law for Ensuring the Quality, Efficacy, and Safety of Drugs and Medical Devices

Approval must be granted to a Legal entity in Japan

4 types of Legal Entity who can be MAH \*: Marketing Authorization Holder

- 100% Subsidiary of Foreign Company in Japan
- Joint Venture with a Japanese company
- Domestic manufacturer named as your distributor
- Designated MAH (D-MAH)

- Business Licenses:
  - Licenses for manufactur
    - 4 classes
  - Licenses for marketing
    - Prescription drugs
    - Other general drugs
  - Three key players

Manufacturing Procedures and Relevant Products

- All / parts of procedures (1) Biologicals (2) Items needed National Assay
  - (3) Recombinant products
- 2 All / parts of procedures for Sterile products
- 3 All / parts of procedures for other than products above
- 4 Only packaging/labelling/storage

- Business Licenses:
  - Licenses for manufa
    - 4 classes
  - Licenses for marketi Prescription
    - Prescription drugs
    - Other general drugs
  - Three key players

Class	Examples
escription drugs	<ul> <li>Antibiotics</li> <li>Anesthesia drug</li> <li>Biologicals / Vaccines</li> <li>Heartworm preventive</li> <li>Hormone medicines</li> <li>NSAIDs, etc.</li> </ul>

- Digestive drugs
- Other drugs Eye drops
  - Flea and tick wormers, etc.

### Business Licenses:

- Licenses for manufacturing
  - 4 classes
- Licenses for marketing
  - Prescription drugs
  - Other general drugs
- Three key players




- Business Licenses:
  - Licenses for manufacturing
    - 4 classes
  - Licenses for marketing
    - Prescription drugs
    - Other general drugs
  - Three key players





# MAH System





# D-MAH System (Designated MAH)





# AHRMS can act...

We maintains the following business licenses:

- Licenses for manufacturing of animal medicines and medical devices
- Licenses for import and marketing of animal medicines and medical devices
- License for wholesale of animal medicines and medical devices
- License for <u>retail</u> of animal medicines and medical devices

# AHRMS can act...

We maintains the following business licenses:

- Licenses for manufacturing of ani as your Manufacturer devices
- as Exporter to yours arketing as your Distributor medical devices
- License for wholesale of animal me as your Wholesaler s

 License for <u>retail</u> of animal modicines and modical devices

- At first, I would like to tell you that Japan is worth investing and introducing new products from you.
- We have to think about the issues by dividing animal medicines into 2 categories.
  - Prescription drugs
  - General drugs

Also, we should think about the distribution channel.

### Pet population Decreasing vs. Market Expansion in Japan (x 1,000 heads) (mio USD) 550 14,000 450 12,000 10,000 350 250 8,000 $\frac{1}{2} \left( \frac{1}{2} \left( \frac{1}{2} \right) \left( \frac{1}{2$ □Pet foods ■Pet medicines ◆Dogs ★Cats

Pet population Decreasing vs. Market Expansion in Japan (from 2008 to 2018)

**Dog Population** Cat Population


-31%

# -11%

Pet foodsPet medicines+81%+71%

(Source: AHRMS, Inc)

# Product Distribution in Japan (Vet Channel)



\*Product: Companion Animal Medicines and Pet Food

(Source: AHRMS, Inc. 2018)

Prescription drugs

- > Vets trust and prefer to buy animal medicines from local wholesalers.
- When a big earthquake occurred in the past, a web-based wholesalers could not deliver any of the products to vets because a home delivery services did not work. They don't have any distribution staffs there.




- But local wholesalers could deliver them though they didn't have enough gas for cars, either.
- $\succ$  It led to a strong trust from vets.

Prescription drugs

≻In Japan, there are 12,000 animal hospitals.

And 64% of them are run by only 1 vet. So, sales reps' regular calls are mostly welcomed except largescale animal hospitals.



Prescription drugs

>In Japan, there are 12,000 animal hospitals.

And 64% of them are run by only 1 vet. So, sales reps' regular calls are mostly welcomed except largescale animal hospitals.

➢In Japan, 80% of the products in vet channel are distributed through nationwide and local wholesalers.

>It is thought to be due to the uniqueness of animal hospitals in Japan.

Distribution Channel

In my suggestion, at present, a foreign manufacturer who enters into Japanese market for the first time should still promote and distribute her products to animal hospitals through domestic wholesalers at first.

≻Main wholesalers:

- Zenoaq (nationwide, direct-selling model)
- Morikubo Yakuhin (local, one of Strongest wholesalers in Kanto area)
- NPC (nationwide wholesaler)
- MP Agro (nationwide wholesaler)

But in the future, telemedicine will dramatically change delivery of services and products! 5. Whether Vets' online shops can be adopted in Japan?

In the US, Covetrus, Vetsource, and Myvetstore are available.
 Pet owners can purchase animal medicines, even prescription drugs, and pet foods through vets' online shops for 24 hours.

In Japan, vets can open online shops but they cannot deal with animal medicines online.

Vets can prescribe animal medicines inside animal hospitals. They do not have the right to sell animal medicines, even flea & tick wormers.

When vets wants to open online shops that can sell animal medicines, they have to hire a pharmacist and receive a retail license by their prefectural government, respectively.

### 5. Whether Vets' online shops can be adopted in Japan?



### 6. How to tackle falsified products



### 6. How to tackle falsified products

South China Morning Post

SIGN IN/UP

Politics

# Chinese vaccine maker found to have forged production data for over four years

Changsheng Bio-tech mixed batches of rabies shots with expired products and hadn't correctly recorded dates or batch numbers since 2014, investigators find




Nectar Gan Published: 8:59pm, 7 Aug, 2018

(Source: South China Morning Post)

6. How to tackle falsified products <u>Packaging firm CEO pleads</u> <u>guilty to veterinary med</u> <u>counterfeiting</u>

Phil Taylor, 04-Apr-2017



The chief executive of a packaging contractor in the US has admitted selling counterfeit animal health product labels and packaging in a federal court. (Source: secure)

(Source: securityindustry.com)

### 6. How to tackle falsified products

In Japan, falsified drugs trademarked "HARVONI" for human hepatitis C were distributed from wholesalers to pharmacies in 2017.

There were no health injury cases because the patient noticed the difference before taking the pills.

MHLW took countermeasures to prevent from the recurrence by strict records of Lot No., Expiry Date, check of bottles unopened, and so on.





### 6. How to tackle falsified products

In veterinary fields in Japan, there are no apparent cases of falsified animal medicines yet. But no one knows.

In recent years, the amount of private import of unapproved animal medicines is dramatically increasing by veterinarians and pet owners.

- >CA vets: generic cancer drugs from China or India
- ➢Pet owners: heartworm preventives from Thailand, Philippines, or NZ
- >Equine vets: pentosan for arthritis, omeprazole for gastric ulcer from AUS

Private import support agents directly deliver the products from abroad in an artful way to slip past the customs. There may be falsified products.

■JMAFF warns the severe risk of private import to both of them.

Tokyo city and NAR have asked me to give presentations about the risk of private import containing counterfeit.

I believe that our continuous enlightenment to them must be the key.

### Thank you for your attention!

Yuki UJIMASA,

DV4MarMSaar

masa@ahrms.jp

imasa@vm3.jp

支

湖

SHIKOTSUKO LAKE